Literature DB >> 27793821

Natural history and effect of therapeutic interventions on subretinal fluid causing foveal detachment in macular telangiectasia type 2.

Hemal Mehta1,2, Simone Müller3, Catherine A Egan2, Simona Degli Esposti2, Adnan Tufail2, Dawn A Sim2, Frank G Holz3, Andrew C Browning4, Winfried M Amoaku4, Peter Charbel Issa3, Mark C Gillies1.   

Abstract

AIM: To report the natural history of subretinal fluid (SRF) causing foveal detachment in macular telangiectasia type 2 (MacTel) and our experience of therapeutic intervention with intravitreal steroids or antivascular endothelial growth factor inhibitor (anti-VEGF) agents in some cases.
METHODS: Retrospective case series. Three of the MacTel study's largest registries were searched to identify eyes with foveal detachment.
RESULTS: We identified 7 eyes from 6 exclusively female patients. The prevalence of foveal detachment was low, present in 1.4% of the assessed MacTel population. Age at presentation ranged from 50 to 66 years. Follow-up ranged from 2 to 8 years. There was late-phase leakage on fluorescein angiography from what was presumed to be ectatic capillaries. The SRF fluctuated without a rapid decline in visual acuity in cases that were not treated. When they were, intravitreal anti-VEGF and steroid therapy in general reduced SRF, at least temporarily, but did not halt the gradual long-term decrease in visual acuity. In one case, optical coherence tomography angiography showed significant reduction in the extent of the predominantly deep intraretinal vascular complex 1 month after anti-VEGF therapy. DISCUSSION AND
CONCLUSIONS: As the natural history of this unusual MacTel phenotype is not characterised by rapid visual decline, intervention with intravitreal anti-VEGF or steroid therapy may not be necessary. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Macula; Retina; Treatment other

Mesh:

Substances:

Year:  2016        PMID: 27793821     DOI: 10.1136/bjophthalmol-2016-309237

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  4 in total

1.  CONCURRENT IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2 AND CENTRAL SEROUS CHORIORETINOPATHY.

Authors:  Alexandre Matet; Suzanne Yzer; Emily Y Chew; Alejandra Daruich; Francine Behar-Cohen; Richard F Spaide
Journal:  Retina       Date:  2018-01       Impact factor: 4.256

2.  Fluorescence Lifetime Imaging Ophthalmoscopy: A Novel Way to Assess Macular Telangiectasia Type 2.

Authors:  Lydia Sauer; Rebekah H Gensure; Martin Hammer; Paul S Bernstein
Journal:  Ophthalmol Retina       Date:  2017-12-08

3.  Case report: internal limiting membrane drape sign masking by foveal detachment in macular telangiectasia type 2.

Authors:  Anmar Abdul-Rahman
Journal:  BMC Ophthalmol       Date:  2020-06-03       Impact factor: 2.209

4.  A Splicing Mutation in Slc4a5 Results in Retinal Detachment and Retinal Pigment Epithelium Dysfunction.

Authors:  Gayle B Collin; Lanying Shi; Minzhong Yu; Nurten Akturk; Jeremy R Charette; Lillian F Hyde; Sonia M Weatherly; Martin F Pera; Jürgen K Naggert; Neal S Peachey; Patsy M Nishina; Mark P Krebs
Journal:  Int J Mol Sci       Date:  2022-02-17       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.